The drugmaker announced topline results from its phase 1 trial of its Amycretin pill on March 7, and following the announcement, Novo Nordisk shares jumped 7.5%, according to The Wall Street Journal.
In the trial, patients taking Amycretin lost about 13% of their body weight in 12 weeks — more than double the weight lost during the same time period with Wegovy, which was about 6%.
The pill is taken once daily and is slated to head into phase 2 trials later this year, the Journal reported. However, Barclays analysts wrote in a note that Novo Nordisk has “not ruled out going [straight] into Phase 3 development,” with the drug.
In addition to the pill, Novo Nordisk also noted it has about 10 other obesity treatments currently in development.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
